Harvard Bioscience, Inc. (HBIO) vs Incannex Healthcare Limited (IXHL)

A side-by-side comparison of Harvard Bioscience, Inc. and Incannex Healthcare Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Harvard Bioscience, Inc. logo
HBIO
Harvard Bioscience, Inc.
$39M
$8.62HealthcareDelayed quote: Oct 6, 2026, 12:12 PM EDT
Incannex Healthcare Limited logo
IXHL
Incannex Healthcare Limited
$38M
$3.21HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT

Total return — HBIO vs IXHL

growth of $100 · dividends reinvested · last 5y
HBIO -84.1% (-30.8%/yr)IXHL -99.8% (-71.8%/yr)HBIO compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $1002023202420252026$16$0
HBIO IXHL

HBIO vs IXHL: by the numbers

  • •HBIO is the larger company ($39M vs $38M market cap).
  • •Both run net losses; IXHL's is the smaller (0.00% vs -11.86% net margin).

Metrics side by side

Valuation

MetricHBIOIXHL
P/S ratio0.44N/A
P/B ratio5.240.57
EV / EBITDA10.58N/A

Profitability

MetricHBIOIXHL
Gross margin58.16%0.00%
Operating margin1.17%0.00%
Net margin-11.86%0.00%
ROE-140.36%-28.65%
ROIC1.99%-32.18%

Growth (annualized)

MetricHBIOIXHL
Revenue CAGR (5Y)-4.62%N/A
Total return CAGR (5Y)-34.33%N/A

Go deeper

Full HBIO analysisFull IXHL analysisInteractive comparison tool

Dig into the metrics

Harvard Bioscience ROEIncannex Healthcare ROEHarvard Bioscience operating marginIncannex Healthcare operating marginHarvard Bioscience revenue growthIncannex Healthcare revenue growthHarvard Bioscience free cash flowIncannex Healthcare free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.